BiochemProbe — Life Science Research Reagents

RMC-4630 free base · Synonyms: SHP2-IN-7 | Vociprotafib

RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway.

For research use only. Not for human or veterinary use.

Target SHP2 Phosphatase
Research area Cancer
Purity >98% Stock Inquire
Data Sheet SDS COA

RMC-4630 structure

CAS No.: 2172652-48-9

Download structure (.mol)

Pack sizes & pricing

Size Price SKU Stock
100 mg USD 385.00 BP-01983-100mg In stock Get quote
250 mg USD 735.00 BP-01983-250mg In stock Get quote
500 mg USD 1,250.00 BP-01983-500mg In stock Get quote
1 g USD 1,980.00 BP-01983-1g In stock Get quote
5 g Inquire BP-01983-5g Inquire Inquire

Need another size or custom synthesis? Request a quote.

Description

RMC-4630 is a potent and selective inhibitor of SHP2, a central node in the RAS signaling pathway.

Biological activity

In Vivo Vociprotafib delays and/or reduces tumor regrowth in mice upon cessation of treatment. Vociprotafib is effective at inhibiting tumor growth in a PDX model that has become resistant to Osimertinib via amplification of c-MET.

Identifiers

SMILES
OCC1=NC(SC2=C(Cl)C(N)=NC=C2)=C(C)N=C1N(CC3)CCC43[C@H](N)[C@H](C)OC4
InChIKey
HISJAYUQVHMWTA-BLLLJJGKSA-N

Specifications

MW (average)
450.9850
Formula
C20H27ClN6O2S
CAS No.
2172652-48-9
Physical state
Solid
Color
Off-white to yellow
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage
Powder -20℃ 2 years; In solvent -20℃ 1 month;

Solubility

Soluble in DMSO 50 mg/mL

Documents

References

[1]. WO2018013597
[2]. Ou S I, et al. A12 the SHP2 inhibitor RMC-4630 in patients with KRAS-mutant non-small cell lung cancer: preliminary evaluation of a first-in-man phase 1 clinical trial[J]. Journal of Thoracic Oncology, 2020, 15(2): S15-S16.
[3]. Smith J A, et al. SHP2 inhibition as the backbone of targeted therapy combinations for the treatment of cancers driven by oncogenic mutations in the RAS pathway[J]. Cancer Research, 2020, 80(16_Supplement): 1943-1943.

Same target

Search SHP2

Same research area

Search Cancer